## Helen Blair Simpson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11893456/publications.pdf

Version: 2024-02-01

172207 161609 3,174 65 29 54 citations h-index g-index papers 67 67 67 3435 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation. JAMA Psychiatry, 2022, 79, 193.	6.0	12
2	The thalamus and its subnuclei—a gateway to obsessive-compulsive disorder. Translational Psychiatry, 2022, 12, 70.	2.4	19
3	Latency to treatment seeking in patients with obsessive-compulsive disorder: Results from a large multicenter clinical sample. Psychiatry Research, 2022, 312, 114567.	1.7	8
4	Subcortical shape in pediatric and adult obsessiveâ€compulsive disorder. Depression and Anxiety, 2022, 39, 504-514.	2.0	1
5	Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Frontiers in Psychiatry, 2022, 13, .	1.3	O
6	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
7	Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder. Current Topics in Behavioral Neurosciences, 2021, 49, 301-329.	0.8	2
8	Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research. Frontiers in Psychiatry, 2021, 12, 626150.	1.3	1
9	White matter microstructure and its relation to clinical features of obsessive–compulsive disorder: findings from the ENIGMA OCD Working Group. Translational Psychiatry, 2021, 11, 173.	2.4	33
10	Heterogeneity in Fear Processing across and within Anxiety, Eating, and Compulsive Disorders. Journal of Affective Disorders, 2020, 275, 329-338.	2.0	13
11	Acute effects of cannabinoids on symptoms of obsessiveâ€compulsive disorder: A human laboratory study. Depression and Anxiety, 2020, 37, 801-811.	2.0	34
12	Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 207-210.	0.7	26
13	Evidence for trial-by-trial dynamic adjustment of task control in unmedicated adults with OCD. Behaviour Research and Therapy, 2020, 126, 103572.	1.6	2
14	Pilot Study Evaluating Critical Time Intervention for Individuals With Hoarding Disorder at Risk for Eviction. Psychiatric Services, 2020, 71, 405-408.	1.1	3
15	Toward identifying reproducible brain signatures of obsessive-compulsive profiles: rationale and methods for a new global initiative. BMC Psychiatry, 2020, 20, 68.	1.1	13
16	Cutting-edge genetics in obsessive-compulsive disorder. Faculty Reviews, 2020, 9, 30.	1.7	8
17	Can delay discounting deliver on the promise of RDoC?. Psychological Medicine, 2019, 49, 190-199.	2.7	117
18	Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning–Based Treatment Outcome in Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2019, 39, 91-93.	0.7	3

#	Article	IF	CITATIONS
19	Impaired generalization of reward but not loss in obsessive-compulsive disorder. Depression and Anxiety, 2019, 36, 121-129.	2.0	17
20	Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York. Behavior Therapy, 2018, 49, 631-641.	1.3	55
21	Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2018, 79, 17111824.	1.1	4
22	What underlies the effect of sleep disruption? The role of alertness in obsessive-compulsive disorder (OCD). Journal of Behavior Therapy and Experimental Psychiatry, 2017, 57, 212-213.	0.6	8
23	To Do or Not to Do? Task Control Deficit in Obsessive-Compulsive Disorder. Behavior Therapy, 2017, 48, 603-613.	1.3	27
24	Patient Preferences and Acceptability of Evidence-Based and Novel Treatments for Obsessive-Compulsive Disorder. Psychiatric Services, 2017, 68, 250-257.	1.1	8
25	Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2017, 78, 466-467.	1.1	13
26	Abnormal hippocampal structure and function in clinical anxiety and comorbid depression. Hippocampus, 2016, 26, 545-553.	0.9	69
27	Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept. American Journal of Psychiatry, 2016, 173, 1239-1241.	4.0	20
28	Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorder. Behavior Therapy, 2016, 47, 474-486.	1.3	23
29	Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention. Psychotherapy and Psychosomatics, 2016, 85, 314-316.	4.0	4
30	Acceptability of treatments and services for individuals with hoarding behaviors. Journal of Obsessive-Compulsive and Related Disorders, 2016, 11, 1-8.	0.7	14
31	Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessiveâ€compulsive disorder. World Psychiatry, 2016, 15, 80-81.	4.8	228
32	Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder?. Journal of Clinical Psychiatry, 2016, 77, 408-409.	1.1	48
33	Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2015, 76, 440-446.	1.1	24
34	Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies. Journal of Clinical Psychiatry, 2015, 76, 1653-1657.	1.1	16
35	Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. Psychiatry Research - Neuroimaging, 2015, 232, 65-70.	0.9	16
36	Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention. Behaviour Research and Therapy, 2015, 68, 76-81.	1.6	39

#	Article	IF	CITATIONS
37	Obsessive-compulsive disorder for ICD-11: proposed changes to the diagnostic guidelines and specifiers. Revista Brasileira De Psiquiatria, 2014, 36, 3-13.	0.9	18
38	Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5. CNS Spectrums, 2014, 19, 10-20.	0.7	37
39	Treatment of Obsessive-Compulsive Disorder in a Nationwide Survey of Office-Based Physician Practice. Psychiatric Services, 2014, 65, 681-684.	1.1	12
40	Prevalence and Correlates of Difficulty Discarding. Journal of Nervous and Mental Disease, 2013, 201, 795-801.	0.5	14
41	Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder. JAMA Psychiatry, 2013, 70, 1190.	6.0	205
42	Does Extended Release Methylphenidate Help Adults With Hoarding Disorder?. Journal of Clinical Psychopharmacology, 2013, 33, 444-447.	0.7	41
43	Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2013, 74, 685-690.	1.1	166
44	Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2013, 74, 464-469.	1.1	24
45	Predictors of Patient Adherence to Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder. Psychotherapy and Psychosomatics, 2012, 81, 124-126.	4.0	46
46	Prevalence of Hoarding Disorder in Individuals at Potential Risk of Eviction in New York City. Journal of Nervous and Mental Disease, 2012, 200, 91-94.	0.5	42
47	THE RDOC PROJECT: A NEW PARADIGM FOR INVESTIGATING THE PATHOPHYSIOLOGY OF ANXIETY. Depression and Anxiety, 2012, 29, 251-252.	2.0	17
48	Patient Adherence to Cognitive-Behavioral Therapy Predicts Long-Term Outcome in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2012, 73, 1265-1266.	1.1	39
49	Serotonin 2A Receptors in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study with [11C]MDL 100907. Biological Psychiatry, 2011, 70, 897-904.	0.7	37
50	Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2011, 72, 567-569.	1.1	46
51	Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder Journal of Consulting and Clinical Psychology, 2011, 79, 247-252.	1.6	176
52	Using Motivational Interviewing to Enhance Treatment Outcome in People With Obsessive-Compulsive Disorder. Cognitive and Behavioral Practice, 2011, 18, 28-37.	0.9	35
53	Development of a Patient Adherence Scale for Exposure and Response Prevention Therapy. Behavior Therapy, 2010, 41, 30-37.	1.3	54
54	Patient Preferences for Obsessive-Compulsive Disorder Treatment. Journal of Clinical Psychiatry, 2010, 71, 1434-1439.	1.1	38

#	Article	IF	CITATIONS
55	Diagnosis and Treatment of a Patient With Both Psychotic and Obsessive-Compulsive Symptoms. American Journal of Psychiatry, 2010, 167, 754-761.	4.0	24
56	Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behaviour Research and Therapy, 2010, 48, 941-948.	1.6	70
57	Pharmacological Treatment of Obsessive-Compulsive Disorder. Current Topics in Behavioral Neurosciences, 2009, 2, 527-543.	0.8	13
58	Statistical choices can affect inferences about treatment efficacy: A case study from obsessiveâ€"compulsive disorder research. Journal of Psychiatric Research, 2008, 42, 631-638.	1.5	19
59	Adding Motivational Interviewing to Exposure and Ritual Prevention for Obsessive–Compulsive Disorder: An Open Pilot Trial. Cognitive Behaviour Therapy, 2008, 37, 38-49.	1.9	48
60	A Randomized, Controlled Trial of Cognitive-Behavioral Therapy for Augmenting Pharmacotherapy in Obsessive-Compulsive Disorder. American Journal of Psychiatry, 2008, 165, 621-630.	4.0	239
61	Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry, 2007, 164, 5-53.	4.0	181
62	Are there reliable neuropsychological deficits in obsessive–compulsive disorder?. Journal of Psychiatric Research, 2006, 40, 247-257.	1.5	84
63	Response Versus Remission in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2006, 67, 269-276.	1.1	196
64	Treatment of Obsessive-Compulsive Disorder by U.S. Psychiatrists. Journal of Clinical Psychiatry, 2006, 67, 946-951.	1.1	87
65	Standard criteria for relapse are needed in obsessive-compulsive disorder. Depression and Anxiety, 2005, 21, 1-8.	2.0	40